MX2016014483A - Nuevos compuestos utiles como inhibidores de s100. - Google Patents

Nuevos compuestos utiles como inhibidores de s100.

Info

Publication number
MX2016014483A
MX2016014483A MX2016014483A MX2016014483A MX2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A
Authority
MX
Mexico
Prior art keywords
inhibitors
novel compounds
compounds useful
disorders
compound
Prior art date
Application number
MX2016014483A
Other languages
English (en)
Spanish (es)
Inventor
Liberg David
East Stephen
Prevost Natacha
Wellmar Ulf
EKBLAD Maria
Bainbridge Marie
Hargrave Jonathan
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of MX2016014483A publication Critical patent/MX2016014483A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
MX2016014483A 2014-05-23 2015-05-22 Nuevos compuestos utiles como inhibidores de s100. MX2016014483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169757 2014-05-23
PCT/EP2015/061468 WO2015177367A1 (en) 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
MX2016014483A true MX2016014483A (es) 2017-01-23

Family

ID=50774707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014483A MX2016014483A (es) 2014-05-23 2015-05-22 Nuevos compuestos utiles como inhibidores de s100.

Country Status (12)

Country Link
US (1) US9771372B2 (Direct)
EP (1) EP2991990B1 (Direct)
JP (1) JP6580074B2 (Direct)
KR (1) KR20170005868A (Direct)
CN (1) CN106414448B (Direct)
AU (1) AU2015261775B2 (Direct)
BR (1) BR112016024749A2 (Direct)
CA (1) CA2948436A1 (Direct)
EA (1) EA030604B1 (Direct)
ES (1) ES2620751T3 (Direct)
MX (1) MX2016014483A (Direct)
WO (1) WO2015177367A1 (Direct)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040982A (zh) 2018-04-27 2020-12-04 国立大学法人冈山大学 抗s100a8/a9抗体及其用途
US11197908B2 (en) 2018-07-17 2021-12-14 The Board Of Trustees Of The University Of Arkansas Peptoids and methods for attenuating inflammatory response
EP4052725A4 (en) 2019-10-30 2024-07-17 National University Corporation Okayama University PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY LUNG DISEASE
WO2023209141A1 (en) 2022-04-29 2023-11-02 Westfälische Wilhelms-Universität Münster Benzo[d]imidazo[1,2-a]imidazoles and their use in diagnosis
WO2025132458A1 (en) 2023-12-18 2025-06-26 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
US7087632B2 (en) * 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
IL154107A0 (en) 2000-07-26 2003-07-31 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0117506D0 (en) 2001-07-18 2001-09-12 Bayer Ag Imidazopyridinones
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
JP4481011B2 (ja) * 2002-03-05 2010-06-16 トランス テック ファーマ,インコーポレイテッド リガンドのrageとの相互作用を阻害する単環式および二環式アゾール誘導体
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
WO2008042282A2 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
EP1986009A1 (en) * 2007-04-26 2008-10-29 Active Biotech AB Screening method
CN101977505A (zh) 2007-06-13 2011-02-16 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
CL2009000116A1 (es) * 2008-01-22 2010-08-27 Takeda Pharmaceutical Compnany Ltd Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable.
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
CN102414180A (zh) 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
JP5808869B2 (ja) 2011-11-03 2015-11-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピペラジン化合物
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
CN106414448A (zh) 2017-02-15
HK1221463A1 (en) 2017-06-02
US20170204098A1 (en) 2017-07-20
CA2948436A1 (en) 2015-11-26
JP2017516772A (ja) 2017-06-22
BR112016024749A2 (pt) 2017-08-15
KR20170005868A (ko) 2017-01-16
EP2991990B1 (en) 2017-02-01
EA201692405A1 (ru) 2017-06-30
EA030604B1 (ru) 2018-08-31
ES2620751T3 (es) 2017-06-29
WO2015177367A1 (en) 2015-11-26
CN106414448B (zh) 2019-04-19
JP6580074B2 (ja) 2019-09-25
EP2991990A1 (en) 2016-03-09
US9771372B2 (en) 2017-09-26
AU2015261775A1 (en) 2016-12-08
AU2015261775B2 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501702B1 (en) Pyrazole amide derivative
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
EA201691421A1 (ru) Гетероарилы и их применение
WO2015054642A3 (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201591509A1 (ru) Ингибиторы cdc7
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
EA031679B9 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
MX2016014483A (es) Nuevos compuestos utiles como inhibidores de s100.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
MX360455B (es) Derivados de n-(heteroaril)-sulfonamida utiles como inhibidores de s100.